There is a need to develop novel therapeutic agents in order to fight infections. Peptide therapeutics are used to fight infectious diseases.
The global peptide based infection therapeutics market is expected to grow in the future owing to factors such as cost effectiveness of peptides, higher efficacy of peptides in managing various disease indications and infections, and can be easily synthesized owing to smaller size.
Moreover, few economic factors such as government policies for startup companies, increasing foreign direct investment, as well as higher investment in healthcare are also driving the global peptide based infection therapeutics market.
The rising prevalence of infectious diseases has resulted in providing an impetus to the use of peptides therapeutics to treat infections. Along with this, emerging biotech and pharmaceutical companies, strong and advanced pipelines and patent expiries are few other aspects impacting the growth of the global peptide based infection therapeutics market positively.
To support this, the advancements in technology and increased research and development and the rising investments in these fields have led to the growing importance of global peptide based infection therapeutics market. North America is expected to show higher attractiveness in this market.
Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective. They are used in the treatment of infections owing to their broad spectrum of activities and mechanisms.
They protect the host from pathogenic microbes and are also referred to as host defense peptides owing to their functionality in protecting the immunity system and fighting against infections.
According to Fact.MR’s research report on the global peptide based infection therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value a bit less than US$ 1.5 Bn.
Domination of North America in the Peptide Based Infection Therapeutics Market
With respect to the global peptide based infection therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share by revenue and is poised to grow at a higher growth rate to register a CAGR during the period of forecast.
North America shows higher market attractiveness; this growth mainly attributed to the higher investment in the healthcare industry along with rapid technological developments.
Latin America and Middle East and Africa (MEA) regions show relatively slow growth rate as compared to North America region and a fairly less market share and this trend is anticipated to continue during the period of forecast, 2017 to 2022.
APEJ to Show Tremendous Activity as Compared to Europe
The Asia-Pacific excluding Japan (APEJ) region is expected to show a rapid growth rate and is expected to register a CAGR of 8.7% during the period of forecast.
The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies.
Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods and technologies to better the health of the patients and enhance patient outcome.
Following Asia-Pacific excluding Japan (APEJ) region, Europe regions also shows good growth rate in the global peptide based infection therapeutics market.
Telaprivir Set to Dominate the Global Market
The telaprivir segment by drug type is expected to dominate the market in terms of market share by revenue, as of 2016 and expected to show a similar trend in 2017 as well.
However, the boceprevir segment grows at a higher rate during the period of forecast as compared to telaprivir yet experiences less market share by revenue comparatively. However, with the higher rate of growth throughout the forecast period, it could be a case that the domination title might shift from telaprivir to boceprivir.
Avail customized purchase options for your needs
Online Pharmacies to Show Robust Growth Rate, Would Just be an Understatement
The online pharmacies segment by distribution channel is anticipated to show exponential growth rate to register a CAGR of 9.2% throughout the period of forecast, 2017 to 2022.
This growth can be attributed towards the increasing awareness of the online concept, its effectiveness, reliability and convenience. However, this segment, still being in its nascent phase, has less market share as compared to other segments in the distribution channel category.
The online segment is also expected to experience a higher gain in the BPS by the end of 2022. The online pharmacies segment reflects the highest growth in the North America region rate as compared to other regions during the period of forecast.
Hospital vs. Retail Pharmacies, a Touch Call to Make
Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market, as per market observations in 2016 and 2017. This trend could keep up with the growth rate that it reflects.
However, the retail pharmacies segment shows a higher growth rate, yet less market share. It is anticipated to reflect a higher growth rate and poised to register a CAGR of 7.9% during the period of forecast of 2017 to 2022.
The regions favoring the growth of the hospital pharmacy segment is APEJ followed by Europe. APEJ is also favorable for retail pharmacies segment, in fact the growth of retail pharmacies in this region is the highest as compared to other regions, as per anticipations.
Asia-Pacific excluding Japan expected to stay strong with respect to all the segments by distribution channel, except for the online pharmacies segment which finds better shelter in North America region.
An Adaptive Approach to Modern-day Research Needs
The report also profiles companies that are expected to remain active in the expansion of the global peptide based infection therapeutics market through 2022, which include
- Vertex Pharmaceuticals Incorporated
- Merck & Co. Inc.
- Parchem Fine & Specialty Chemicals.
(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.